Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.
The development of effective new treatments is greatly facilitated by the understanding of the mechanisms of disease. In rheumatoid arthritis, there has been progress in understanding its immunology, the HLA class II predisposition including the 'shared epitope' and more recently in unders...
| Autors principals: | , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
2002
|
| _version_ | 1826259986892718080 |
|---|---|
| author | Feldmann, M Maini, R |
| author_facet | Feldmann, M Maini, R |
| author_sort | Feldmann, M |
| collection | OXFORD |
| description | The development of effective new treatments is greatly facilitated by the understanding of the mechanisms of disease. In rheumatoid arthritis, there has been progress in understanding its immunology, the HLA class II predisposition including the 'shared epitope' and more recently in understanding the importance of proinflammatory cytokines. Here we review our work in defining TNFalpha as a therapeutic target in rheumatoid arthritis, from an understanding of molecular pathogenesis in vitro, to formal proof in the clinic in vivo. There is now extensive clinical use of anti-TNFalpha biologicals for severe rheumatoid arthritis in the US and Europe. |
| first_indexed | 2024-03-06T18:58:30Z |
| format | Journal article |
| id | oxford-uuid:12b51006-6acf-4f4a-8d4a-ce00f050e982 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:58:30Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:12b51006-6acf-4f4a-8d4a-ce00f050e9822022-03-26T10:09:23ZDiscovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:12b51006-6acf-4f4a-8d4a-ce00f050e982EnglishSymplectic Elements at Oxford2002Feldmann, MMaini, RThe development of effective new treatments is greatly facilitated by the understanding of the mechanisms of disease. In rheumatoid arthritis, there has been progress in understanding its immunology, the HLA class II predisposition including the 'shared epitope' and more recently in understanding the importance of proinflammatory cytokines. Here we review our work in defining TNFalpha as a therapeutic target in rheumatoid arthritis, from an understanding of molecular pathogenesis in vitro, to formal proof in the clinic in vivo. There is now extensive clinical use of anti-TNFalpha biologicals for severe rheumatoid arthritis in the US and Europe. |
| spellingShingle | Feldmann, M Maini, R Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. |
| title | Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. |
| title_full | Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. |
| title_fullStr | Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. |
| title_full_unstemmed | Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. |
| title_short | Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. |
| title_sort | discovery of tnf alpha as a therapeutic target in rheumatoid arthritis preclinical and clinical studies |
| work_keys_str_mv | AT feldmannm discoveryoftnfalphaasatherapeutictargetinrheumatoidarthritispreclinicalandclinicalstudies AT mainir discoveryoftnfalphaasatherapeutictargetinrheumatoidarthritispreclinicalandclinicalstudies |